Loading page
Loading page
Loading substance route
Significant risk of blackout and respiratory depression above 125 mg. Tolerance develops rapidly with repeated use.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Moderate abuse potential with risk of psychological dependence. Compulsive redosing has been reported as an after effect of use.
Physical dependence develops with chronic use, potentially occurring within weeks of regular dosing at low or high doses. Withdrawal syndrome resembles benzodiazepine and alcohol withdrawal, with symptoms ranging from anxiety, tremors, and insomnia to severe manifestations including hallucinations, delirium, psychosis, seizures, and extreme muscle rigidity resembling neuroleptic malignant syndrome. Abrupt discontinuation is not advised; gradual tapering is necessary.
Baclofen has low toxicity relative to dose when used alone. However, fatal overdose may occur when combined with other depressants such as alcohol, opioids, or benzodiazepines. Overdose symptoms include altered mental status, respiratory depression, seizures, hypothermia, and coma sometimes mimicking brain death. Overdose may require intubation, with duration of mechanical ventilation correlating with serum baclofen levels.
| Species | Route | Value |
|---|---|---|
| rat | oral | 145 mg/kg |
CNS depression including sedation, somnolence, and ataxia occurs at therapeutic and recreational doses; overdose may cause altered mental status, hypothermia, and coma that can mimic brain death.
Respiratory depression and insufficiency may occur, particularly at higher doses or in overdose; risk increases significantly when combined with other CNS depressants.
Cardiovascular depression is possible at high doses; overdose may cause bradycardia, tachycardia, hypertension, and cardiac conduction abnormalities, though these effects are uncommon.
Rhabdomyolysis may occur if baclofen use is stopped abruptly after chronic administration; this is a withdrawal complication rather than a direct toxic effect during use.
Baclofen should be avoided in chronic kidney disease and end-stage renal disease as even small doses can cause excessive toxicity due to impaired drug clearance; this represents accumulation toxicity rather than direct nephrotoxicity.
Psychosis, hallucinations (auditory, visual, and tactile), delusions, delirium, confusion, disorientation, and mania may occur during withdrawal from chronic use, particularly with abrupt discontinuation. These psychiatric symptoms are associated with the withdrawal syndrome rather than acute intoxication.
Seizures may occur in overdose or with abrupt discontinuation after chronic use. Withdrawal-related seizures are a serious concern requiring gradual tapering when discontinuing therapy. High-dose combinations with sedatives may also precipitate de novo seizures.
Baclofen was first synthesized in 1962 by Swiss chemist Heinrich Keberle at Ciba-Geigy in Basel, Switzerland. The compound was designed with the intention of enhancing the lipophilicity of gamma-aminobutyric acid (GABA) to enable penetration of the blood-brain barrier, with epilepsy treatment as…
WHO List of Essential Medicines
In 2014, the French drug agency ANSM issued a temporary recommendation permitting baclofen's use in treating alcohol dependence. In 2018, the substance received formal Marketing Authorization for alcoholism treatment when other therapies have proven ineffective.
Regulated as a prescription medication. Storing or transporting baclofen without a valid prescription may constitute a criminal offense and could result in prosecution.
Can be obtained at pharmacies without requiring a prescription, making it more accessible than in most other countries.
Classified as a prescription medicine under Anlage 1 AMVV (Arzneimittelverschreibungsverordnung). Available through pharmacies with a valid medical prescription.
Regulated as a prescription medication. Available through pharmacies with a valid prescription from a licensed healthcare provider.
Not a controlled substance under the Controlled Substances Act. Approved by the FDA in 1977 and available only with a valid prescription. As of 2023, it ranked among the most commonly prescribed medications in the country with over 7 million prescriptions.
15 sources cited